Holds one active US DMF for relugolix, filing since 2024. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds one active US DMF for relugolix, filing since 2024. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for relugolix, filing since 2026. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Holds one active US DMF for relugolix, filing since 2022. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 6 markets.
Holds one active US DMF for relugolix, filing since 2024. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for relugolix, filing since 2024. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds 2 active US DMFs for relugolix, filing since 2025. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
This page filters the worldwide Relugolix manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Ask Fred which manufacturers are on record for relugolix and what filings they hold.
Chat with Fred, your AI analyst